Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Veravas appoints new members to its advisory Board
June 26, 2019 Off

Veravas appoints new members to its advisory Board

By BusinessWire

Veravas, Inc., an emerging diagnostic company, appointed eight members to its Advisory Board

Fotivda, EUSA Pharma Overview 2017-2026
June 26, 2019 Off

Fotivda, EUSA Pharma Overview 2017-2026

By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Fotivda” report has been added to ResearchAndMarkets.com’s offering. Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) is an oral…

Acceleron expects top-line results in the Q1 2020 for Sotatercept in pulmonary arterial hypertension
June 26, 2019 Off

Acceleron expects top-line results in the Q1 2020 for Sotatercept in pulmonary arterial hypertension

By BusinessWire

Acceleron has completed target enrollment of patients with pulmonary arterial hypertension (PAH) in the PULSAR Phase 2 trial of sotatercept

June 26, 2019 Off

German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma

By BusinessWire

National reimbursement decision for Optune® in Germany anticipated in 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the…

June 26, 2019 Off

Faron Pharma: early to estimate efficacy of Traumakine due to limited number of evaluable patients

By Dino Mustafić

Faron Pharmaceuticals’s CEO Markku Jalk said it was disappointing to learn about the magnitude of steroid use in the patient population as RAAA is considered as a traumatic condition and to have only limited inflammatory impact on disease development.

Zealand Pharma kicks off dosing patients in testing SBS potential treatment
June 26, 2019 Off

Zealand Pharma kicks off dosing patients in testing SBS potential treatment

By Dino Mustafić

Zealand Pharma has dosed the first out of 64 healthy patients, in a Phase 1 clinical test of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS).

Intensity Therapeutics to work with Merck on its lead prduct combined with Keytruda
June 26, 2019 Off

Intensity Therapeutics to work with Merck on its lead prduct combined with Keytruda

By BusinessWire

Phase 1/2 clinical trial to evaluate Intensity’s INT230-6 in combination with KEYTRUDA® (pembrolizumab) for multiple solid tumor types

Contrad Swiss in new partnership with Dr JO Serrentino
June 26, 2019 Off

Contrad Swiss in new partnership with Dr JO Serrentino

By BusinessWire

Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino.

June 26, 2019 Off

Celltrion Adopts Veeva Vault eTMF for Greater Visibility into Trial Activities

By BusinessWire

Leading South Korean biopharmaceutical modernizes trial operations to maintain inspection readiness and have a comprehensive view of study status PLEASANTON,…

June 26, 2019 Off

Decibel Therapeutics Appoints Healthcare Industry Veteran Christine A. Poon to its Board of Directors

By BusinessWire

BOSTON–(BUSINESS WIRE)–Decibel Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for hearing loss and balance disorders, today announced the appointment…

Posts pagination

Previous 1 … 3,046 3,047 3,048 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine